BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19675882)

  • 1. [Sodium-iodine symporter in thyroid, normal and cancer tissues and its relation to nuclear medicine and to gene cloning treatment].
    Foujilas C; Marakaki C; Syrmos N
    Hell J Nucl Med; 2009; 12(2):189-93. PubMed ID: 19675882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sodium iodide symporter: its pathophysiological and therapeutic implications.
    Spitzweg C; Morris JC
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].
    Spitzweg C
    Internist (Berl); 2003 Apr; 44(4):396-402, 404-8, 410-1. PubMed ID: 12914397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
    Carvalho DP; Ferreira AC
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
    Dohán O; Carrasco N
    Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium iodide symporter: its role in nuclear medicine.
    Chung JK
    J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The practical relevance of the sodium iodide symporter].
    Spitzweg C
    Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minireview: The sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid.
    Bizhanova A; Kopp P
    Endocrinology; 2009 Mar; 150(3):1084-90. PubMed ID: 19196800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies.
    Heufelder AE; Morgenthaler N; Schipper ML; Joba W
    Thyroid; 2001 Sep; 11(9):839-47. PubMed ID: 11575853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.
    Ravera S; Reyna-Neyra A; Ferrandino G; Amzel LM; Carrasco N
    Annu Rev Physiol; 2017 Feb; 79():261-289. PubMed ID: 28192058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa.
    Spitzweg C; Joba W; Eisenmenger W; Heufelder AE
    J Clin Endocrinol Metab; 1998 May; 83(5):1746-51. PubMed ID: 9589686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
    Kogai T; Taki K; Brent GA
    Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A perspective view of sodium iodide symporter research and its clinical implications.
    Riesco-Eizaguirre G; Santisteban P
    Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different expression of sodium-iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR).
    Shi XZ; Xue L; Jin X; Xu P; Jia S; Shen HM
    J Endocrinol Invest; 2017 Jan; 40(1):41-48. PubMed ID: 27531173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
    Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
    J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sodium/iodide symporter: state of the art of its molecular characterization.
    Darrouzet E; Lindenthal S; Marcellin D; Pellequer JL; Pourcher T
    Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):244-53. PubMed ID: 23988430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
    Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium iodide symporter in health and disease.
    Shen DH; Kloos RT; Mazzaferri EL; Jhian SM
    Thyroid; 2001 May; 11(5):415-25. PubMed ID: 11396700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid regulation of thyroid sodium-iodide symporter activity by thyrotrophin and iodine.
    Ferreira AC; Lima LP; Araújo RL; Müller G; Rocha RP; Rosenthal D; Carvalho DP
    J Endocrinol; 2005 Jan; 184(1):69-76. PubMed ID: 15642784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.